Bender Robert & Associates’s Evolus EOLS Stock Holding History

Bender Robert & Associates’s Portfolio EOLS Stock Details EOLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,070	Closed	-$103K	–	42
2026 Q1	$103K	Buy	+25,070	New	+$121K	0.02%	45
2025 Q4	–	Sell	-25,070	Closed	-$154K	–	42
2025 Q3	$154K	Hold	25,070	–	–	0.03%	46
2025 Q2	$231K	Buy	+25,070	New	+$257K	0.05%	40
2025 Q1	–	Sell	-25,070	Closed	-$277K	–	43
2024 Q4	$277K	Buy	+25,070	New	+$353K	0.07%	40
2024 Q1	–	Sell	-25,070	Closed	-$264K	–	46
2023 Q4	$264K	Hold	25,070	–	–	0.07%	42
2023 Q3	$229K	Hold	25,070	–	–	0.07%	44
2023 Q2	$182K	Hold	25,070	–	–	0.05%	47
2023 Q1	$212K	Buy	+25,070	New	+$227K	0.07%	51
2022 Q4	–	Sell	-25,070	Closed	-$202K	–	50
2022 Q3	$202K	Hold	25,070	–	–	0.08%	48
2022 Q2	$291K	Buy	+25,070	New	+$296K	0.11%	44
2021 Q2	–	Sell	-25,000	Closed	-$325K	–	48
2021 Q1	$325K	Buy	+25,000	New	+$230K	0.1%	48

Other funds holding EOLS

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Bender Robert & Associates's EOLS Position: Q2 2026 in Review

Bender Robert & Associates sold out of Evolus (EOLS) in Q2 2026, closing a stake of 25,070 shares — an estimated $103K sold.

Bender Robert & Associates first reported a position in EOLS in Q1 2021 and held it in 11 quarters. The position peaked at $325K in Q1 2021. 158 funds tracked by Wall St. Rank hold EOLS as of Q2 2026.

Bender Robert & Associates reported no remaining Evolus position as of Q2 2026 after selling out during the quarter.
Bender Robert & Associates sold 25,070 Evolus shares in Q2 2026, an estimated $103K.
Bender Robert & Associates first reported a position in Evolus in Q1 2021 and held it in 11 quarters.
Bender Robert & Associates's Evolus position peaked at $325K in Q1 2021.
158 funds tracked by Wall St. Rank held Evolus as of Q2 2026.

Based on Bender Robert & Associates's 13F filing for Q2 2026, filed 30 Jul 2026.